Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexa B Schrock

Showing results (101-110 of 130) with videos related to

Pageof 13
Sort By:
Oncology|October 21, 2016
Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 FusionVivek Subbiah, Oliver Holmes, Kyle Gowen, et al.
Journal of Gastrointestinal Oncology|October 12, 2019
Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsyGerald Li, Dean Pavlick, Jon H Chung, et al.
Cancer|August 11, 2021
Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancerAndrea Necchi, Vito Cucchiara, Petros Grivas, et al.
The Oncologist|October 29, 2017
<i>ALK</i> Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted TherapyJeffrey S Ross, Siraj M Ali, Omotayo Fasan, et al.
Nature Communications|November 18, 2018
RET rearrangements are actionable alterations in breast cancerBhavna S Paratala, Jon H Chung, Casey B Williams, et al.
JCI Insight|April 20, 2017
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patientsVivek Subbiah, Muhammad Rizwan Khawaja, David S Hong, et al.
Histopathology|February 29, 2024
Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable resultsDouglas A Mata, Jessica K Lee, Vignesh Shanmugam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2020
U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid TumorsKyriakos P Papadopoulos, Erkut Borazanci, Alice T Shaw, et al.
JCO Precision Oncology|February 1, 2022
Atypical <i>RAS</i> Mutations in Metastatic Colorectal CancerFilippo Pietrantonio, Rona Yaeger, Alexa B Schrock, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2017
Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic ProfilingAlexa B Schrock, Shuyu D Li, Garrett M Frampton, et al.
Pageof 13

Showing results (101-110 of 130) with videos related to

Sort By:
Pageof 13
Oncology|October 21, 2016
Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 FusionVivek Subbiah, Oliver Holmes, Kyle Gowen, et al.
Journal of Gastrointestinal Oncology|October 12, 2019
Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsyGerald Li, Dean Pavlick, Jon H Chung, et al.
Cancer|August 11, 2021
Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancerAndrea Necchi, Vito Cucchiara, Petros Grivas, et al.
The Oncologist|October 29, 2017
<i>ALK</i> Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted TherapyJeffrey S Ross, Siraj M Ali, Omotayo Fasan, et al.
Nature Communications|November 18, 2018
RET rearrangements are actionable alterations in breast cancerBhavna S Paratala, Jon H Chung, Casey B Williams, et al.
JCI Insight|April 20, 2017
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patientsVivek Subbiah, Muhammad Rizwan Khawaja, David S Hong, et al.
Histopathology|February 29, 2024
Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable resultsDouglas A Mata, Jessica K Lee, Vignesh Shanmugam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2020
U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid TumorsKyriakos P Papadopoulos, Erkut Borazanci, Alice T Shaw, et al.
JCO Precision Oncology|February 1, 2022
Atypical <i>RAS</i> Mutations in Metastatic Colorectal CancerFilippo Pietrantonio, Rona Yaeger, Alexa B Schrock, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2017
Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic ProfilingAlexa B Schrock, Shuyu D Li, Garrett M Frampton, et al.
Pageof 13